IL2 and allergic disease: Interleukin(IL)‐2 complexed to distinct anti‐IL‐2 antibodies represents such a strong IL‐2R agonist.23, 24 Distinct anti‐IL‐2 mAbs, which bind to functionally important epitopes of IL‐2, not only increase the half‐life of IL‐2 but also direct the selective expansion of certain T cell subsets, most prominently Tregs.23, 25 This would suggest IL‐2/αIL‐2 complexes as a treatment option for allergic diseases.